Ambicion

AMBICION Co., Ltd.

MENU

News

Ghent University and AMBICION Entered into a Patent Assignment Agreement on the US rights to the Galacto-pyranosyl compounds.

May 31, 2018

Ghent University (Ghent, Belgium) and AMBICION (Tokyo, Japan) announced that they entered into a patent assignment agreement on the US rights to the Galacto-pyranosyl compounds as developed by the groups of Prof. Serge Van Calnebergh and Prof. Dirk Elewaut.
According to the agreement, AMBICIO...

AMBICION has completed raising funds from Regional Health Care Industry Support Fund and TOHO HOLDINGS

April 18, 2018

AMBICION Co., Ltd. announced that it has completed raising funds from Regional Health Care Industry Support Fund and TOHO HOLDINGS CO., LTD. through third-party allocation of new shares.
With this capital increase, AMBICION accelerates its development programs of Natural Killer T (NKT) cell-t...

AMBICION and RIKEN Enter into the Global Exclusive Licensing Agreements for Natural Killer T (NKT) Cell-Targeted Anti-Cancer Therapy

March 30, 2018

AMBICION (CEO: Yoshiyuki Saito) announced that RIKEN (President: Hiroshi Matsumoto) and AMBICION entered into the global exclusive licensing agreements on RIKEN patent regarding Natural Killer T (NKT) cell-targeted anti-cancer therapy. Under the terms of the licensing agreement, AMBICION has been ...
1 2